The Calithera Biosciences, Inc. (CALA) Stock Rating Upgraded by BidaskClub

Xavier Trudeau
Juillet 17, 2017

They now have a Dollars 12 price target on the stock. The business had revenue of $4.19 million during the quarter, compared to analysts' expectations of $1.40 million.

Multiple company employees have indulged in significant insider trading. Colgate-Palmolive Company (NYSE:CL) has risen 6.23% since July 13, 2016 and is uptrending. It has underperformed by 41.10% the S&P500. Calithera Biosciences, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP, BUS.

About 299,823 shares traded.

Calithera Biosciences (NASDAQ:CALA) last posted its earnings results on Tuesday, May 9th. This technical setup was reported by We have $19.86 PT which if reached, will make NASDAQ:CALA worth $26.89M more. Therefore 14% are positive. Calithera Biosciences had 8 analyst reports since July 24, 2015 according to SRatingsIntel. On Thursday, July 6 the stock rating was maintained by Jefferies with "Hold". The stock now has an average rating of "Buy" and a consensus price target of $14.17. Sterne Agee CRT initiated Colgate-Palmolive Company (NYSE:CL) on Tuesday, July 21 with "Buy" rating. (NASDAQ:CALA), with 2 analysts believing it is a strong buy. Its up 0.12, from 0.93 in 2016Q3. The insider now directly owns 15,560 shares worth $295,640. Connor Clark And Lunn Inv Management holds 480,924 shares. Wesbanco Retail Bank Incorporated accumulated 11,827 shares. Blackrock Institutional Trust Com Na, California-based fund reported 260,883 shares. Asset Mgmt One reported 0.24% in Colgate-Palmolive Company (NYSE:CL). Connor Clark And Lunn Investment Mgmt Ltd reported 10,200 shares or 0% of all its holdings. 5,250 are held by Hall Laurie J Trustee. Patten Gru invested 2.8% of its portfolio in Visa Inc (NYSE:V). 1492 Capital Mngmt Lc owns 17,259 shares or 0.46% of their United States portfolio. Norris Perne & French Llp Mi owns 4,000 shares. First Pacific Advisors Limited Liability holds 0.16% or 568,673 shares in its portfolio. Endurance Wealth Management has invested 0.47% in Colgate-Palmolive Company (NYSE:CL).

Since February 27, 2017, it had 14 buys, and 0 sales for $2.00 million activity. $527,971 worth of Colgate-Palmolive Company (NYSE:CL) was sold by SADOVE STEPHEN I. 3,833 shares were sold by Verduin Patricia, worth $258,842 on Wednesday, February 15. It increased, as 86 investors sold Visa Inc shares while 540 reduced holdings.

A number of equities analysts have recently issued reports on CALA shares. JMP Securities restated an "outperform" rating and set a $12.00 target price on shares of Calithera Biosciences in a research report on Tuesday, March 28th. Citigroup upgraded the stock to "Neutral" rating in Tuesday, January 24 report. The rating was maintained by H.C. Wainwright on Tuesday, March 28 with "Buy". The stock of Calithera Biosciences Inc (NASDAQ:CALA) has "Buy" rating given on Monday, June 12 by H.C. Wainwright.

Investors sentiment increased to 2.06 in 2016 Q4. KCG Holdings Inc. purchased a new stake in Calithera Biosciences during the first quarter valued at approximately $144,000. 58 funds opened positions while 117 raised stakes. The Texas-based Bridgeway Capital Management Inc has invested 0.01% in the stock.

Calithera Biosciences, Inc. (NASDAQ:CALA) has accumulated 18.55% over the course of one week. Northern reported 17,457 shares. Adage Capital Partners Gp L.L.C. owns 3.64 million shares or 0.03% of their U.S. portfolio. Paloma Partners Management Co purchased a new stake in Calithera Biosciences during the first quarter valued at approximately $160,000. Moreover, Adage Prns Grp Limited Liability has 0.03% invested in Calithera Biosciences Inc (NASDAQ:CALA) for 3.64M shares. Franklin Street Advsrs Nc holds 124,580 shares or 0.07% of its portfolio. Manufacturers Life Ins The stated it has 108 shares. Torray Ltd stated it has 2.26% in Visa Inc (NYSE:V). If Calithera Biosciences, Inc.

Ratings analysis reveals 50% of Calithera Biosciences's analysts are positive.

SunPower Corporation (NASDAQ:SPWR) trades at $10.16 having a market capitalization of $1.43 billion. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. CALA's current price-earnings ratio amounts above the average P/E ratio of 159.66 times earnings. The Company is involved in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

D'autres rapports CampDesrEcrues

Discuter de cet article